To assess the utility of 2-[ 18 F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to detect recurrent disease in the follow-up of patients with well-differentiated thyroid cancer (WDTC) who have negative diagnostic 131 I scans and abnormal thyroglobulin levels.
Summary Background Data
In general, patients with WDTC have an excellent long-term prognosis when appropriate surgical treatment and follow-up are carried out. After total thyroid ablation, whole-body 131 I scintigraphy and measurement of serum thyroglobulin are useful diagnostic tools to detect persistent or recurrent malignancy. In case of tumor dedifferentiation, decreased or lost iodine-accumulating ability may lead to false-negative 131 I scanning results. The diagnostic and therapeutic delay is responsible for a poor prognosis in this subgroup of patients. Efforts have been made in the search for suitable imaging modalities capable of early detection of recurrent thyroid carcinoma.
Methods
The authors prospectively analyzed 24 patients with WDTC, negative results of whole-body 131 I scintigraphy, and elevated serum thyroglobulin concentrations. Attenuation-corrected whole-body FDG-PET scans from the neck to the upper legs were performed. In addition, all patients underwent cervical ultrasonography. The results of the imaging studies were compared with histopathologic findings. If no resection of the suspicious lesion was carried out, computed tomography data were used as control criteria.
Results
Overall, FDG-PET disclosed 38 hot spots. The sensitivity of the method was 94.6%, but the specificity was lower (25.0%). The diagnostic accuracy was 87.8%. There were three false-positive results in two patients with benign cervical lymph nodes. In one patient with regional lymph node metastases in the neck, two false-negative results were obtained. Ultrasound classified both findings as malignant, however. Because of unexpected findings, FDG-PET suggested potential modification of the surgical management in nine patients. Distant metastases could be disclosed using FDG-PET in only three patients.
Conclusions
FDG-PET is a useful diagnostic tool in the follow-up of thyroidectomized patients with WDTC, negative 131 I scanning results, and abnormal serum thyroglobulin concentrations. The method detects metastatic disease in 94.6% of cases. PET results changed surgical tactics in a significant number of patients. Accurate staging of locoregional cancer recurrence in the neck may be consummately obtained by concomitant analysis of PET and ultrasound results.
Routine follow-up of patients with well-differentiated thyroid cancer (WDTC) includes whole-body 131 I scintig-raphy and serum thyroglobulin determination. Limitations in detecting locoregional recurrence or distant metastases occur when progressive dedifferentiation of thyroid carcinoma cells leads to a loss of iodine-concentrating capacity. In the course of the disease, false-negative radioactive iodine scans are seen in up to 20% of patients with original WDTC. In contrast to the otherwise encouraging overall prognosis of WDTC, this subpopulation of patients may have a poor outcome because of delayed detection of tumor relapse and consecutive surgical treatment. In addition, metastatic thyroid lesions that fail to concentrate radioactive iodine exhibit more aggressive biologic behavior.
Several conventional imaging techniques, such as ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), have been used to localize tumor deposits in the presence of negative 131 I scans and clinical suspicion based on an increased serum thyroglobulin concentration in the absence of thyroglobulin antibodies or disturbance of the thyroglobulin recovery test. However, all these anatomic imaging tools can produce varied and inconsistent results, especially in patients undergoing repeated surgical procedures. In the neck, where metastases most frequently occur, the sensitivity and specificity of ultrasound are strongly dependent on subjective factors. 1 For CT and MRI, the overall error rate of assessment of cervical lymph node metastases is 7.5%. 2 The results of nonspecific scintigraphic examinations with 201 Tl and 99m Tc-sestamibi are unsatisfactory, with an average reported sensitivity of 60%.
Recently, numerous reports have shown high utility of 2-[ 18 F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the detection and staging of different malignant tumors: soft tissue sarcomas; 3 cutaneous melanoma; 4 pancreatic, 5 breast, 6 colorectal, 7 esophageal, 8 head and neck, 9 and non-small-cell lung cancer; 10 neuroendocrine tumors; 11 metastases of unknown primary origin; 12 and non-Hodgkin's lymphoma. 13 The ability of FDG-PET to visualize tumors is based on the increased carbohydrate metabolism of malignant cells, with subsequent elevated glucose utilization and selective 18 FDG uptake. Once phosphorylated by hexokinase, FDG accumulates intracellularly because it cannot be metabolized as glucose. Although well-differentiated thyroid malignancies with sufficient 131 I uptake are associated with decreased glucose metabolism, and in contrast, dedifferentiated tumors lacking the possibility of 131 I accumulation show elevated glucose utilization, FDG-PET has been also introduced in the follow-up of thyroid cancer. 14 -17 Our study assesses the experience with FDG-PET in the detection of recurrent thyroid carcinoma in the presence of a negative 131 I scan and pathologic serum thyroglobulin values.
PATIENTS AND METHODS

Patients
Between September 1992 and December 2000, we prospectively studied 189 patients treated for WDTC at the University Hospitals of Hamburg and Essen, Germany. We identified patients who had undergone thyroidectomy and in whom at least one postoperative radioiodine treatment had been performed. We also included in this study a subgroup of 25 patients negative by 131 I scintigraphy with suspicion of tumor recurrence as a result of detectable serum thyro-globulin levels in the absence of thyroglobulin antibodies or disturbance of the thyroglobulin recovery test. There were 17 female patients and 8 male patients, aged 8 to 81 years (mean age 52.8 years). Before surgery, all patients were evaluated by history, clinical examination, chest radiograph, standard laboratory tests (blood count, electrolytes, liver and kidney function, blood coagulation), cervical ultrasound (in some instances with fine-needle aspiration cytology), and FDG-PET. All patients with hot spots indicating distant metastases underwent CT scanning to prove the FDG-PET results.
Surgery
The same surgeon (except for two patients) performed all surgical procedures. In patients with cervical lymph node metastases operated on with curative intent, compartmentoriented systemic lymphadenectomy was performed. If treatment was palliative, lymph node metastases were removed selectively. Both patients with mediastinal and pulmonary findings were operated on using a transsternal approach. Because of the location of the parapharyngeal tumor, one patient required a transoral approach. All tissue removed was histopathologically and immunohistochemically examined and reviewed by two pathologists.
FDG-PET
After an overnight fast to minimize blood insulin levels and glucose uptake of normal tissue, plasma glucose levels were determined before PET studies. The blood glucose level did not exceed 130 mg/mL before the examination in any patient. Imaging started 60 minutes after intravenous administration of 400 MBq FDG. Attenuation-corrected whole-body (skull to upper legs) PET scans in two-dimensional mode were acquired using a full-ring high-resolution ECAT EXACT HR plus scanner (CTI, Knoxville, TN) with a 15.2-cm axial field of view and seven or eight bed positions, with 8 minutes of emission and 4 minutes of transmission per bed position. Emission data reconstruction was performed with the ECAT 7.2 software package using FORE/OSEM (one iteration, 30 subsets). Data were finally smoothed with 10-mm Gaussian kernel. Reprojected views and coronal, transaxial, and sagittal slices were reconstructed from the data set. Images were interpreted and screened for the hot spots of hypermetabolic abnormalities by two experienced independent nuclear medicine physicians. Standardized uptake values (SUV; ratio of measured radioactivity concentration in an area of interest to the estimated body tracer concentration, assuming a uniform distribution through the entire body volume) were calculated for suspicious lesions. Hypermetabolic foci were assessed as probably malignant, especially in cases of high (Ͼ2.5) SUV, depending on localization, structure, and size and when the possibility of inflammatory alterations was considered unlikely. The results were compared with his- 
CT Scanning
Helical CT scans of the chest were performed using a standard CT scanner (Phillips SR 8000, Eindhoven, The Netherlands). After intravenous injection of 100 mL contrast medium (Ultravist 300, Schering, Berlin, Germany), 5-mm contiguous image slices were obtained in 3 seconds.
Scintigraphy
Whole-body scanning was performed 3 to 5 days after oral administration of 400 to 1,000 MBq 131 I (for diagnostic purposes) or 5 to 10 days after oral administration of 3,000 to 10,000 MBq 131 I (for therapeutic purposes) under hypothyroid conditions (4 weeks of levothyroxine withdrawal, thyroid stimulating hormone (TSH) Ͼ30 mU/L), using a whole-body dual-head gamma camera (Bodyscan, Siemens, Munich, Germany).
Ultrasonography
Cervical ultrasound studies were carried out as previously reported by our group. 1 Briefly, we used a high-resolution imaging device with a small-part real-time transducer (7.5 L 40; Siemens, Erlangen, Germany) with a frequency of 9 MHz in B-mode. Nodular blood flow was measured with color Doppler sonography (PRF 1250 Hz for conventional color Doppler and 868 Hz for power mode).
Statistical Analysis
We determined the sensitivity, specificity, predictive value, and diagnostic accuracy of FDG-PET as follows. Sensitivity was defined as the number of true-positive cases divided by the sum of the true-positive cases and the falsenegative cases (ϫ100%). Specificity was defined as the number of true-negative cases divided by the sum of the true-negative cases and the false-positive cases (ϫ100%). Positive predictive value was defined as the number of true-positive cases divided by the sum of the true-positive cases and false-positive cases (ϫ100%). Negative predictive value was defined as the number of true-negative cases divided by the sum of the true-negative cases and falsenegative cases (ϫ100%). Diagnostic accuracy was defined as the sum of the true-positive cases and true-negative cases divided by the total number of cases (ϫ100%).
RESULTS
Twenty-five patients with WDTC, a negative 131 I wholebody scan, and abnormal serum thyroglobulin levels underwent FDG-PET in an attempt to localize the suspected tumor recurrence. In addition, ultrasound of the cervical region was performed in all but one patient. An 8-year-old boy with a suspicious tumor mass in the neck, in whom FDG-PET disclosed advanced multivisceral metastases, was excluded from further study and underwent chemotherapy. The remaining 24 patients underwent one or more surgical interventions during the observation period; a total of 31 operations were performed. Details of clinical information, localization of suspected tumor recurrence, cervical ultrasound findings, results of FDG-PET, and results of histopathologic examination are summarized in Table 1 .
In nine patients (37.5%), hot spots on FDG-PET scans were seen in the cervicolateral region only. Four patients (16.6%) had an isolated focus of uptake in the location of the thyroid bed. FDG-PET detected cervicolateral and distant hot spots in six patients (25%), and in an additional three patients (12.5%) locoregional and distant tumor involvement was presumed ( Figs. 1-3) . CT scanning confirmed pathologic lesions in six of the patients with FDG-PET uptake indicating distant metastases.
In one patient (patient 4), in whom cervical ultrasound showed pathologic locoregional and cervicolateral findings, FDG-PET provided negative results. In another patient (patient 12), suspicious tissue appeared on a CT scan of the chest carried out for other reasons. FDG-PET imaging performed subsequently provided negative results. At the time of surgery, nonspecific mediastinal lymphoid tissue was found. Overall, FDG-PET showed 38 sites of radiopharmaceutical uptake in 22 patients.
FDG-PET correctly identified recurrent cancer in 35 locations (true positive). In one patient (patient 12) FDG-PET produced a true-negative result, in one patient it was falsely negative in two locations, and in two patients it provided false-positive results, in two and in one locations, respectively (Fig. 4) . The overall sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy are shown in Table 2 .
Because of unsuspected findings on FDG-PET, we altered our initial surgical strategy in nine patients. In six patients, systematic cervical lymphadenectomy or removal of locoregional tumor recurrence was planned. All six patients, however, showed additional mediastinal, skeletal, or lung metastases, so solely selective lymph node dissection or palliative tumor debulking in the neck was performed. PET correctly detected distant metastases-all of them not seen on CT scan but confirmed by histopathologic examination at the time of surgery-in three other patients, in whom only a cervical tumor mass was expected.
DISCUSSION
Most patients with WDTC treated surgically and followed up by 131 I whole-body scintigraphy and serum thyroglobulin determination have an excellent prognosis. On the basis of data from more than 50,000 patients with WDTC, the National Cancer Data Base reported a 10-year overall survival rate of 76% to 93%. 18 However, a consid-erable diagnostic dilemma occurs when thyroid carcinoma cells dedifferentiate and lose the capacity to accumulate radioactive iodine. Because the utility of FDG-PET has been substantiated for various malignant tumors, and on account of the significant glucose consumption of thyroid cancer cells, this imaging modality has also become valuable for detecting residual or recurrent thyroid cancer. Potential limitations of FDG-PET are presumed in patients with diabetes or glucagonoma syndrome.
Joensuu and Ahonen 19 in 1987 and Sisson et al 20 in 1993 were among the first to published reports on patients with thyroid cancer imaged by FDG-PET. In a prospective study of 41 patients, Feine 21 found a sensitivity of 95% when FDG-PET and 131 I whole-body scintigraphy were performed. An inverse relationship was found between uptake of 131 I and 18 FDG in most of the metastases, causing a flip-flop phenomenon. It was postulated that functional tumor differentiation is associated with low 18 FDG uptake and remaining 131 I uptake, whereas dedifferentiation is associated with the loss of iodine-accumulating capacity and an increase in metabolism from progressive growth. Similar observations were made by Grünwald et al, 22 who found Localization of tumor recurrence was classified as local (thyroid bed), regional (cervical lymph node metastases), or distant (mediastinal tumor mass, bone metastasis, and lung metastasis).
FDG-PET to be superior to 131 I in poorly differentiated carcinoma. In the view of Dietlein et al, 17 the utility of FDG-PET varied among different organs, being highest in cervical lymph nodes and lowest in small pulmonary metastases. In 1997 a Consensus Conference reviewed the experience of different German centers with FDG-PET in oncology. For the thyroid, the statements were based on the data from a multicentric retrospective study enrolling 220 patients with WDTC. 21 FDG-PET results were compared with those of 131 I scintigraphy and 201 Tl/ 99m Tc sestamibi scintigraphy in terms of sensitivity, specificity, predictive values, and accuracy. 22 The overall sensitivity of FDG-PET was 75%; it increased to 85% when only patients with negative 131 I scans were included. When PET was correlated with thyroglobulin levels (thyroglobulin serum levels), the specificity was up to 100% for thyroglobulin levels of more than 5g/L, although the sensitivity remained the same. Overall, the participants found FDG-PET to be superior to other imaging modalities in patients with negative radioiodine scanning results, especially when thyroglobulin concentrations were abnormal and thyroid hormone was not withdrawn.
In agreement with these observations, Chung et al 23 found that FDG-PET was highly accurate in detecting recurrent or metastatic thyroid cancer in a group of 33 patients with cervical or distant metastases. Among individuals with negative 131 I scans, FDG-PET was superior to thyroglobulin in terms of sensitivity and specificity. With respect to dif-ferent locations of tumor lesions, FDG-PET was able to detect cervical lymph node metastases in 87.9% and mediastinal metastases in 33.3% of the patients with tumors still accumulating radioiodine, whereas they were detected in only 61.5% and 22.2%, respectively, with 131 I scanning.
Our study underlines the superiority of FDG-PET in the management of patients with WDTC, in whom failed 131 I concentration interferes with standard follow-up and treatment in case of tumor recurrence. Based on our data from 24 patients, the sensitivity of the method was 94.6%. In the report previously published by our group the sensitivity was only 84.6%; however, at that time only 13 patients were tested. 1 The low specificity of 25.0% and negative predictive value of 33.3% might be explained by the fact that there was only one true-negative result. As for the detection of local or regional cancer recurrence, the method had three false-positive and two false-negative results. In both patients with false-positive results, histopathologic examination of the lesions revealed benign lymphatic tissue with an inflammatory component. False-positive FDG-PET scans are well-recognized problems in the acute or chronic local inflammatory state, especially if previous surgery has been performed. 24 In addition, it has been reported that FDG can be trapped not only in malignant tissue but also in granu- Figure 1 . A 70-year-old woman with follicular carcinoma. Cervical ultrasound indicated regional lymph node metastases. To confirm this finding and to determine whether there were additional lesions, positron emission tomography was performed. It showed hot spots in the neck, the upper mediastinum, and the sternum (arrow). lomatous disease, in the presence of osteomyelitis and abdominal abscesses. 16 In our clinical setting, ultrasound in connection with fine-needle biopsy remains the first-line diagnostic method for assessing local cancer recurrence or cervical lymph node metastases because of its true-positive rate of 95.3% and the low costs ot the method. 1 Because ultrasound results vary considerably from institution to institution, however, FDG- 17 found that 9 of 27 cervical lymph node metastases less than 1 cm in diameter were identifiable in PET, Wang et al 25 observed that most of the false-negative FDG-PET results were obtained in cases of minimal cervical adenopathy.
We found FDG-PET to be very sensitive in the search for distant metastases in the setting of negative 131 I scanning results; for us, this is the most important indication for the use of this new imaging modality. In 37.5% of the study group patients, unexpected distant lesions were disclosed, leading to alterations in our initial surgical plans. Based on FDG-PET results only, three patients with distant metastases were able to be treated with potentially curative intent. There are no data on FDG-PET's sensitivity in relation to different anatomic locations of malignant distant lesions. Comparing the sensitivity of conventional 99m Tc-methylene diphosphonate bone scanning, a common method for searching for skeletal metastases, with FDG-PET, Schirrmeister et al 26 found the latter method to be more sensitive and recommended using it when possible. There is evidence, however, that in tumors still accumulating radioiodine, FDG-PET has a lower positive rate in detecting distant metastases than radioiodine scanning.
Our data strongly support the recommendation that FDG-PET should be used as the whole-body imaging method of choice in the follow-up of patients with thyroid cancer suspected of having tumor recurrence in the presence of negative 131 I scanning results, 25, 27 particularly because it seems to be superior to other whole-body imaging techniques (i.e., 201 Tl and 99m Tc-sestamibi scintigraphy 16, 21, [27] [28] [29] ). 
